Futility monitoring for randomized clinical trials with non-proportional hazards: An optimal conditional power approach

被引:1
|
作者
Wang, Xiaofei [1 ]
George, Stephen L. [1 ]
机构
[1] Duke Univ, Sch Med, Dept Biostat & Bioinformat, 2424 Erwin Rd,Suite 1102, Durham, NC 27705 USA
关键词
Average hazard ratio; clinical trial design; delayed treatment effect; futility rules; non-proportional hazards; SAMPLE-SIZE; SURVIVAL; DESIGN; TESTS;
D O I
10.1177/17407745231181908
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Standard futility analyses designed for a proportional hazards setting may have serious drawbacks when non-proportional hazards are present. One important type of non-proportional hazards occurs when the treatment effect is delayed. That is, there is little or no early treatment effect but a substantial later effect. Methods We define optimality criteria for futility analyses in this setting and propose simple search procedures for deriving such rules in practice. Results We demonstrate the advantages of the optimal rules over commonly used rules in reducing the average number of events, the average sample size, or the average study duration under the null hypothesis with minimal power loss under the alternative hypothesis. Conclusion Optimal futility rules can be derived for a non-proportional hazards setting that control the loss of power under the alternative hypothesis while maximizing the gain in early stopping under the null hypothesis.
引用
收藏
页码:603 / 612
页数:10
相关论文
共 45 条
  • [41] A non-parametric approach to predict the recruitment for randomized clinical trials: an example in elderly inpatient settings (vol 24, 189, 2024)
    Villasante-Tezanos, Alejandro
    Kuo, Yong-Fang
    Kurinec, Christopher
    Li, Yisheng
    Yu, Xiaoying
    BMC MEDICAL RESEARCH METHODOLOGY, 2024, 24 (01)
  • [42] A key risk indicator approach to central statistical monitoring in multicentre clinical trials: method development in the context of an ongoing large-scale randomized trial
    Valdés-Márquez Elsa
    Hopewell C Jemma
    Landray Martin
    Armitage Jane
    Trials, 12 (Suppl 1)
  • [43] What is the optimal approach to a non-culprit stenosis after ST-elevation myocardial infarction - Conservative therapy or upfront revascularization? An updated meta-analysis of randomized trials
    Narayanan, Mahesh Anantha
    Reddy, Yogesh N. V.
    Sundaram, Varun
    Reddy, Yuvaram N. V.
    Baskaran, Janani
    Agnihotri, Kanishk
    Badheka, Apurva
    Patel, Nilesh
    Deshmukh, Abhishek
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 216 : 18 - 24
  • [44] Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials
    Huang, Le-Tian
    Cao, Rui
    Wang, Yan-Ru
    Sun, Li
    Zhang, Xiang-Yan
    Guo, Yi-Jia
    Zhao, Jian-Zhu
    Zhang, Shu-Ling
    Jing, Wei
    Song, Jun
    Han, Cheng-Bo
    Ma, Jietao
    BMC CANCER, 2021, 21 (01)
  • [45] Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials
    Le-Tian Huang
    Rui Cao
    Yan-Ru Wang
    Li Sun
    Xiang-Yan Zhang
    Yi-Jia Guo
    Jian-Zhu Zhao
    Shu-Ling Zhang
    Wei Jing
    Jun Song
    Cheng-Bo Han
    Jietao Ma
    BMC Cancer, 21